Peptide Decoding
New?New to peptides?Start here →
Decoding

Pemvidutide_Dosage, benefits & legal status

Also known as ALT-801

Published July 22, 2026 · Updated October 4, 2026

An experimental weekly shot for weight loss and fatty liver.

Weight loss / liverGLP-1 / glucagon agonistInvestigational
Common vial size10 mg
Dose1.2 up to 2.4 mg per week (trial doses)
FrequencyWeekly
RouteUnder the skin (subcutaneous)
StatusInvestigational
CycledNot cycled in the trials

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

See how this dose compares across the library →

01

What is Pemvidutide?

Plain language first. The technical label stays, but it never stands alone.

Overview

It curbs appetite and nudges metabolism to burn more, studied for both weight loss and fatty-liver disease. It is still experimental.

The technical version

Pemvidutide is a dual GLP-1 and glucagon agonist.

What it's used for

An experimental weekly shot for weight loss and fatty-liver disease, working on two pathways.

02

How does Pemvidutide work?

What it does in the body, and where.

Pemvidutide combines GLP-1 with glucagon, and is being developed for liver disease as much as for weight.

  1. 01
    GLP-1 reduces intake, glucagon raises expenditure
    The same two-lever design as survodutide.
  2. 02
    Liver fat is the primary target
    Glucagon acts directly on the liver, which is why this pairing keeps being tested in fatty liver disease rather than only in obesity.
  3. 03
    Phase 2 results only.
Anatomical illustration highlighting metabolic organs
WHAT THIS COMPOUND ACTS ON:
GLP-1Fullness, slower stomachglucagonBurns stored fuel
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Weight lossInvestigational
  • Fatty liver disease (MASH)Investigational

The published record

Research index

36

Papers and trials about Pemvidutide

Searched: pemvidutide, ALT-801.

25 papers tagged human · 6 not reviews or lab · 3 clinical trial publications

16 registered trials · 5 with posted results

Furthest stage reached: Phase 3, under way

Compare this against the whole library →

In animals2
In the lab0
Reviews6
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.

Pemvidutide vial rendering
Compound field notes

At a glance

Four things to know about Pemvidutide

01

Evidence

Investigational

02

Category

Weight loss and metabolic

03

Common vial

10 mg

04

Half-life

About 110 hours

04

How much, and do you cycle it?

The range, and whether you take breaks.

1.2 up to 2.4 mg per week (trial doses), weekly. Not cycled in the trials Trial dose

Given continuously for the whole study period: MOMENTUM, 48 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

About 110 hoursTrial protocol

From an investor presentation rather than a published pharmacokinetic paper.

Source: Altimmune phase 1 corporate disclosure, September 2021. ADA 2022 abstract 334-OR

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Printed on the vial.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: 1.2 up to 2.4 mgTrial dose

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW24 / 100 units
07

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized Pemvidutide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 31% charged residues, 34% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • No formal contraindications established
  • Pregnancy

Stop and get help

These are emergencies. Seek care.
  • Vomiting that will not stop
  • Severe stomach pain that spreads to your back
  • Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing

Common effects

Expected, and usually mild.
  • Nausea and vomiting are the main effects, mostly mild to moderate
  • Low rates of diarrhea and constipation
  • The manufacturer reports no meaningful rise in heart rate, which is a company-reported claim

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is Pemvidutide approved?

And where the numbers on this page come from.

No. Pemvidutide is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

  • Approval status
    Investigational
  • Route
    Under the skin (subcutaneous)
  • Checked
    22 July 2026
  • Dose
    From published clinical trials. Not approved by a regulator for this dose.
  • Vial size
    From what vendors typically list; not a recommendation.
  • Sources
    None traced yet.

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

Guides for this compound

Sources

No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence

Beyond these, 36 records are indexed. Browse the records